Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25mg; levodopa 250mg - tablet - active: carbidopa monohydrate 27mg equivalent to carbidopa 25mg levodopa 250mg excipient: crospovidone indigo carmine magnesium stearate microcrystalline cellulose pregelatinised maize starch - levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/ carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome. when therapeutic response to levodopa alone is irregular, and signs and symptoms of parkinson's disease are not evenly controlled throughout the day, substitution of levodopa/carbidopa usually is effective in reducing fluctuations in response. by reducing certain adverse reactions produced by levodopa alone, levodopa/carbidopa permits more patients to obtain adequate relief of the symptoms of parkinson's disease. levodopa/carbidopa is also indicated for patients with parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (vitamin b6).

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mylan institutional inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer’s recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions: drug interactions). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer’s recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions: drug interactions). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - indications and usage: carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. contraindications: nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least 2 weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hydrochloride) (see precautions: drug interactions ).     carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least 2 weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hydrochloride) (see precautions: drug interactions). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least 2 weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hydrochloride) (see precautions: drug interactions). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

schwarz pharma - carbidopa (unii: mnx7r8c5vo) (carbidopa - unii:mnx7r8c5vo), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - tablet, orally disintegrating - 25 mg - parcopa®   is indicated in the treatment of the symptoms of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. parcopa®   is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. however, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. although the administration of carbidopa permits control of parkinsonism and parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing naus

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bluepoint laboratories - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 50 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions ). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

physicians total care, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa - unii:mnx7r8c5vo), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa 10 mg - carbidopa and levodopa tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. this product is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa therapy. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is benefic

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; crospovidone; pregelatinised maize starch; indigo carmine aluminium lake - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.